ASCO 2023 | Has molecular profiling of brain tumors revealed any potentially-actionable targets?

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses actionable targets of brain tumors. Only a small subset of gliomas are treatable, whereby BRAFV600E are present in 3% of glioblastomas and a higher percentage of pediatric low-grade gliomas. Additionally, NTRK fusions and FGFR-TACC fusions are potentially treatable with targeted agents. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.